1 | adjunctive | 3,077 |
2 | add-on | 1,534 |
3 | manipulative | 400 |
4 | on-demand | 293 |
5 | auxiliary | 258 |
6 | exposure-based | 104 |
7 | abortive | 68 |
8 | triple-combination | 41 |
9 | augmentative | 26 |
10 | decongestive | 26 |
11 | insulin-based | 23 |
12 | guideline-adherent | 18 |
13 | program-adult | 16 |
14 | twice-yearly | 16 |
15 | acei-based | 15 |
16 | anma | 14 |
17 | icp-targeted | 14 |
18 | osteoplastic | 13 |
19 | enterra | 12 |
20 | etiotropic | 12 |
21 | provider-administered | 12 |
22 | injective | 11 |
23 | iv/oral | 10 |
24 | directly-observed | 9 |
25 | mitraclip® | 9 |
26 | ultrarush | 9 |
27 | added-on | 8 |
28 | icp-directed | 8 |
29 | kali | 8 |
30 | self-start | 8 |
31 | action-observation | 7 |
32 | antiamyloid | 7 |
33 | cognitive-linguistic | 7 |
34 | khalifa | 7 |
35 | nonrecommended | 6 |
36 | mutual-aid | 5 |
37 | water-immersion | 5 |
38 | ala-ipl | 4 |
39 | ambulance-based | 4 |
40 | angina-guided | 4 |
41 | basal-only | 4 |
42 | cpg-based | 4 |
43 | non-comprehensive | 4 |
44 | optoelectric | 4 |
45 | therapy+standard | 4 |
46 | 26-wks | 3 |
47 | disease-directed | 3 |
48 | energy-correction | 3 |
49 | fda-recommended | 3 |
50 | hai-based | 3 |
51 | hdl-based | 3 |
52 | ozone-oxygen | 3 |
53 | panitumumab-based | 3 |
54 | program-based | 3 |
55 | program/adult | 3 |
56 | rifabutin-based | 3 |
57 | videogame-based | 3 |
58 | aba-based | 2 |
59 | adds-on | 2 |
60 | adjuctive | 2 |
61 | adjunctive-to-insulin | 2 |
62 | anti-obstructive | 2 |
63 | atmosphere/temperature | 2 |
64 | blood-contacting | 2 |
65 | conditioning-enhanced | 2 |
66 | docetaxel/sunitinib | 2 |
67 | efficatious | 2 |
68 | estrogen-deprivation | 2 |
69 | insomnia-specific | 2 |
70 | institutional-based | 2 |
71 | mild.both | 2 |
72 | mitomycin-based | 2 |
73 | nanoelectroablation | 2 |
74 | non-dtic-containing | 2 |
75 | operant-behavioural | 2 |
76 | oral/enema | 2 |
77 | oxaliplatin/5-fu/lv | 2 |
78 | raav1.nt-3 | 2 |
79 | rotem-guided | 2 |
80 | scit-related | 2 |
81 | 'feedback-informed | 1 |
82 | +/-aminoglycoside | 1 |
83 | 41,561 | 1 |
84 | 500µg | 1 |
85 | 60-second-delayed | 1 |
86 | a/lps | 1 |
87 | ad-mediated | 1 |
88 | addon | 1 |
89 | adjuvent | 1 |
90 | after-loading | 1 |
91 | ahr-guided | 1 |
92 | allergen-based | 1 |
93 | alternative/additive | 1 |
94 | alternative/adjunct | 1 |
95 | anthracycline-combination | 1 |
96 | anti-fapα | 1 |
97 | antilatency | 1 |
98 | antiplated | 1 |
99 | apheresis-based | 1 |
100 | balloon-only | 1 |
101 | cell-on-a-chip | 1 |
102 | critical-illness-related | 1 |
103 | diasafe | 1 |
104 | doses.laba | 1 |
105 | dual-agonist | 1 |
106 | edema-controlling | 1 |
107 | ehdaa2 | 1 |
108 | empirical-supported | 1 |
109 | epochmaking | 1 |
110 | equine-assisted | 1 |
111 | er+α-blocker | 1 |
112 | erlotinib-maintenance | 1 |
113 | ethylsuccinate-sulfisoxazole | 1 |
114 | extended/maintenance | 1 |
115 | eye-drop-based | 1 |
116 | fdc/ | 1 |
117 | first-line-lipid-altering | 1 |
118 | gi-based | 1 |
119 | glicazide | 1 |
120 | heamophilia | 1 |
121 | high-pressure-oxygen | 1 |
122 | hno3/h2o | 1 |
123 | hyperalgesia-inducing | 1 |
124 | hyporelaxation | 1 |
125 | imipenem-based | 1 |
126 | intention-to-continue | 1 |
127 | investigations-for | 1 |
128 | ischemia-based | 1 |
129 | maintenance-tailored | 1 |
130 | methamphetamine-focused | 1 |
131 | mrghifu | 1 |
132 | mrsa-directed | 1 |
133 | mucin-5 | 1 |
134 | nanog‑targeted | 1 |
135 | nanolithographic | 1 |
136 | near-curative | 1 |
137 | needed-including | 1 |
138 | neuro-cytoprotective | 1 |
139 | non-cocaine-containing | 1 |
140 | nonpharmalogical | 1 |
141 | nonrosuavastatin | 1 |
142 | oc183b2-targeted | 1 |
143 | open-choice | 1 |
144 | pancreatoprotective | 1 |
145 | paucidose | 1 |
146 | potassium-maintenance | 1 |
147 | preantiretroviral | 1 |
148 | species-oriented | 1 |
149 | study.slt | 1 |
150 | tb-preventive | 1 |
151 | tgf-beta-antagonistic | 1 |
152 | triple-component | 1 |
153 | triple/quadruple | 1 |
154 | two-method | 1 |
155 | usual- | 1 |
156 | wls-r | 1 |
157 | “the | 1 |
1 | 'feedback-informed | 1 |
2 | +/-aminoglycoside | 1 |
3 | 26-wks | 3 |
4 | 41,561 | 1 |
5 | 500µg | 1 |
6 | 60-second-delayed | 1 |
7 | a/lps | 1 |
8 | aba-based | 2 |
9 | abortive | 68 |
10 | acei-based | 15 |
11 | action-observation | 7 |
12 | ad-mediated | 1 |
13 | add-on | 1,534 |
14 | added-on | 8 |
15 | addon | 1 |
16 | adds-on | 2 |
17 | adjuctive | 2 |
18 | adjunctive | 3,077 |
19 | adjunctive-to-insulin | 2 |
20 | adjuvent | 1 |
21 | after-loading | 1 |
22 | ahr-guided | 1 |
23 | ala-ipl | 4 |
24 | allergen-based | 1 |
25 | alternative/additive | 1 |
26 | alternative/adjunct | 1 |
27 | ambulance-based | 4 |
28 | angina-guided | 4 |
29 | anma | 14 |
30 | anthracycline-combination | 1 |
31 | anti-fapα | 1 |
32 | anti-obstructive | 2 |
33 | antiamyloid | 7 |
34 | antilatency | 1 |
35 | antiplated | 1 |
36 | apheresis-based | 1 |
37 | atmosphere/temperature | 2 |
38 | augmentative | 26 |
39 | auxiliary | 258 |
40 | balloon-only | 1 |
41 | basal-only | 4 |
42 | blood-contacting | 2 |
43 | cell-on-a-chip | 1 |
44 | cognitive-linguistic | 7 |
45 | conditioning-enhanced | 2 |
46 | cpg-based | 4 |
47 | critical-illness-related | 1 |
48 | decongestive | 26 |
49 | diasafe | 1 |
50 | directly-observed | 9 |
51 | disease-directed | 3 |
52 | docetaxel/sunitinib | 2 |
53 | doses.laba | 1 |
54 | dual-agonist | 1 |
55 | edema-controlling | 1 |
56 | efficatious | 2 |
57 | ehdaa2 | 1 |
58 | empirical-supported | 1 |
59 | energy-correction | 3 |
60 | enterra | 12 |
61 | epochmaking | 1 |
62 | equine-assisted | 1 |
63 | er+α-blocker | 1 |
64 | erlotinib-maintenance | 1 |
65 | estrogen-deprivation | 2 |
66 | ethylsuccinate-sulfisoxazole | 1 |
67 | etiotropic | 12 |
68 | exposure-based | 104 |
69 | extended/maintenance | 1 |
70 | eye-drop-based | 1 |
71 | fda-recommended | 3 |
72 | fdc/ | 1 |
73 | first-line-lipid-altering | 1 |
74 | gi-based | 1 |
75 | glicazide | 1 |
76 | guideline-adherent | 18 |
77 | hai-based | 3 |
78 | hdl-based | 3 |
79 | heamophilia | 1 |
80 | high-pressure-oxygen | 1 |
81 | hno3/h2o | 1 |
82 | hyperalgesia-inducing | 1 |
83 | hyporelaxation | 1 |
84 | icp-directed | 8 |
85 | icp-targeted | 14 |
86 | imipenem-based | 1 |
87 | injective | 11 |
88 | insomnia-specific | 2 |
89 | institutional-based | 2 |
90 | insulin-based | 23 |
91 | intention-to-continue | 1 |
92 | investigations-for | 1 |
93 | ischemia-based | 1 |
94 | iv/oral | 10 |
95 | kali | 8 |
96 | khalifa | 7 |
97 | maintenance-tailored | 1 |
98 | manipulative | 400 |
99 | methamphetamine-focused | 1 |
100 | mild.both | 2 |
101 | mitomycin-based | 2 |
102 | mitraclip® | 9 |
103 | mrghifu | 1 |
104 | mrsa-directed | 1 |
105 | mucin-5 | 1 |
106 | mutual-aid | 5 |
107 | nanoelectroablation | 2 |
108 | nanog‑targeted | 1 |
109 | nanolithographic | 1 |
110 | near-curative | 1 |
111 | needed-including | 1 |
112 | neuro-cytoprotective | 1 |
113 | non-cocaine-containing | 1 |
114 | non-comprehensive | 4 |
115 | non-dtic-containing | 2 |
116 | nonpharmalogical | 1 |
117 | nonrecommended | 6 |
118 | nonrosuavastatin | 1 |
119 | oc183b2-targeted | 1 |
120 | on-demand | 293 |
121 | open-choice | 1 |
122 | operant-behavioural | 2 |
123 | optoelectric | 4 |
124 | oral/enema | 2 |
125 | osteoplastic | 13 |
126 | oxaliplatin/5-fu/lv | 2 |
127 | ozone-oxygen | 3 |
128 | pancreatoprotective | 1 |
129 | panitumumab-based | 3 |
130 | paucidose | 1 |
131 | potassium-maintenance | 1 |
132 | preantiretroviral | 1 |
133 | program-adult | 16 |
134 | program-based | 3 |
135 | program/adult | 3 |
136 | provider-administered | 12 |
137 | raav1.nt-3 | 2 |
138 | rifabutin-based | 3 |
139 | rotem-guided | 2 |
140 | scit-related | 2 |
141 | self-start | 8 |
142 | species-oriented | 1 |
143 | study.slt | 1 |
144 | tb-preventive | 1 |
145 | tgf-beta-antagonistic | 1 |
146 | therapy+standard | 4 |
147 | triple-combination | 41 |
148 | triple-component | 1 |
149 | triple/quadruple | 1 |
150 | twice-yearly | 16 |
151 | two-method | 1 |
152 | ultrarush | 9 |
153 | usual- | 1 |
154 | videogame-based | 3 |
155 | water-immersion | 5 |
156 | wls-r | 1 |
157 | “the | 1 |
1 | usual- | 1 |
2 | fdc/ | 1 |
3 | 41,561 | 1 |
4 | ehdaa2 | 1 |
5 | raav1.nt-3 | 2 |
6 | mucin-5 | 1 |
7 | doses.laba | 1 |
8 | khalifa | 7 |
9 | heamophilia | 1 |
10 | oral/enema | 2 |
11 | anma | 14 |
12 | enterra | 12 |
13 | docetaxel/sunitinib | 2 |
14 | insomnia-specific | 2 |
15 | nanolithographic | 1 |
16 | etiotropic | 12 |
17 | optoelectric | 4 |
18 | osteoplastic | 13 |
19 | tgf-beta-antagonistic | 1 |
20 | cognitive-linguistic | 7 |
21 | conditioning-enhanced | 2 |
22 | angina-guided | 4 |
23 | rotem-guided | 2 |
24 | ahr-guided | 1 |
25 | fda-recommended | 3 |
26 | nonrecommended | 6 |
27 | 'feedback-informed | 1 |
28 | provider-administered | 12 |
29 | maintenance-tailored | 1 |
30 | aba-based | 2 |
31 | ischemia-based | 1 |
32 | panitumumab-based | 3 |
33 | ambulance-based | 4 |
34 | videogame-based | 3 |
35 | exposure-based | 104 |
36 | cpg-based | 4 |
37 | hai-based | 3 |
38 | acei-based | 15 |
39 | gi-based | 1 |
40 | institutional-based | 2 |
41 | hdl-based | 3 |
42 | program-based | 3 |
43 | imipenem-based | 1 |
44 | allergen-based | 1 |
45 | mitomycin-based | 2 |
46 | insulin-based | 23 |
47 | rifabutin-based | 3 |
48 | eye-drop-based | 1 |
49 | apheresis-based | 1 |
50 | methamphetamine-focused | 1 |
51 | ad-mediated | 1 |
52 | critical-illness-related | 1 |
53 | scit-related | 2 |
54 | antiplated | 1 |
55 | mrsa-directed | 1 |
56 | disease-directed | 3 |
57 | icp-directed | 8 |
58 | oc183b2-targeted | 1 |
59 | icp-targeted | 14 |
60 | nanog‑targeted | 1 |
61 | species-oriented | 1 |
62 | empirical-supported | 1 |
63 | equine-assisted | 1 |
64 | directly-observed | 9 |
65 | 60-second-delayed | 1 |
66 | mutual-aid | 5 |
67 | antiamyloid | 7 |
68 | on-demand | 293 |
69 | two-method | 1 |
70 | therapy+standard | 4 |
71 | open-choice | 1 |
72 | erlotinib-maintenance | 1 |
73 | potassium-maintenance | 1 |
74 | extended/maintenance | 1 |
75 | +/-aminoglycoside | 1 |
76 | glicazide | 1 |
77 | diasafe | 1 |
78 | “the | 1 |
79 | ethylsuccinate-sulfisoxazole | 1 |
80 | triple/quadruple | 1 |
81 | atmosphere/temperature | 2 |
82 | paucidose | 1 |
83 | intention-to-continue | 1 |
84 | non-comprehensive | 4 |
85 | manipulative | 400 |
86 | near-curative | 1 |
87 | augmentative | 26 |
88 | injective | 11 |
89 | pancreatoprotective | 1 |
90 | neuro-cytoprotective | 1 |
91 | adjunctive | 3,077 |
92 | adjuctive | 2 |
93 | anti-obstructive | 2 |
94 | alternative/additive | 1 |
95 | tb-preventive | 1 |
96 | abortive | 68 |
97 | decongestive | 26 |
98 | hyperalgesia-inducing | 1 |
99 | after-loading | 1 |
100 | needed-including | 1 |
101 | epochmaking | 1 |
102 | edema-controlling | 1 |
103 | non-dtic-containing | 2 |
104 | non-cocaine-containing | 1 |
105 | first-line-lipid-altering | 1 |
106 | blood-contacting | 2 |
107 | 500µg | 1 |
108 | ultrarush | 9 |
109 | mild.both | 2 |
110 | kali | 8 |
111 | nonpharmalogical | 1 |
112 | preantiretroviral | 1 |
113 | iv/oral | 10 |
114 | operant-behavioural | 2 |
115 | ala-ipl | 4 |
116 | ozone-oxygen | 3 |
117 | high-pressure-oxygen | 1 |
118 | adjunctive-to-insulin | 2 |
119 | nonrosuavastatin | 1 |
120 | add-on | 1,534 |
121 | added-on | 8 |
122 | adds-on | 2 |
123 | addon | 1 |
124 | water-immersion | 5 |
125 | nanoelectroablation | 2 |
126 | triple-combination | 41 |
127 | anthracycline-combination | 1 |
128 | estrogen-deprivation | 2 |
129 | action-observation | 7 |
130 | hyporelaxation | 1 |
131 | energy-correction | 3 |
132 | hno3/h2o | 1 |
133 | cell-on-a-chip | 1 |
134 | wls-r | 1 |
135 | er+α-blocker | 1 |
136 | investigations-for | 1 |
137 | 26-wks | 3 |
138 | a/lps | 1 |
139 | efficatious | 2 |
140 | alternative/adjunct | 1 |
141 | study.slt | 1 |
142 | program-adult | 16 |
143 | program/adult | 3 |
144 | triple-component | 1 |
145 | guideline-adherent | 18 |
146 | adjuvent | 1 |
147 | self-start | 8 |
148 | dual-agonist | 1 |
149 | mrghifu | 1 |
150 | oxaliplatin/5-fu/lv | 2 |
151 | antilatency | 1 |
152 | basal-only | 4 |
153 | balloon-only | 1 |
154 | twice-yearly | 16 |
155 | auxiliary | 258 |
156 | mitraclip® | 9 |
157 | anti-fapα | 1 |